Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 3/20 | 0.51 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.46 |
| ▸ | SYK | P43405 | 5/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | TLR4 | O00206 | 1/20 | 0.44 |
| ▸ | TLR2 | O60603 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 3/20 | 0.43 |
| ▸ | MET | P08581 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.42 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4318791 | 0.87 | PARP10 (0.53) | PARP10KDM4EALDH1A1SMN1; SMN2PARP14 | |
| SCHEMBL3274391 | 0.86 | PARP10 (0.52) | PARP10KDM4EALDH1A1SMN1; SMN2PARP14 | |
| Lithium SCHEMBL3274398 | 0.86 | PARP10 (0.52) | PARP10KDM4EALDH1A1SMN1; SMN2PARP14 | |
| SCHEMBL3275073 | 0.84 | PARP10 (0.51) | PARP10KDM4EALDH1A1SMN1; SMN2PARP14 | |
| Lithium Ion SCHEMBL3590770 | 0.79 | MAOB (0.42) | PARP10PPARGPARP14MAPTMAOB | |
| SCHEMBL8308756 | 0.75 | TLR4 (0.53) | PARP10PPARGKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL31424381 | 0.75 | KDM4E (0.50) | PARP10KDM4EALDH1A1SMN1; SMN2SYK | |
| SCHEMBL29468851 | 0.75 | KDM4E (0.50) | PARP10KDM4EALDH1A1SMN1; SMN2SYK | |
| SCHEMBL2325950 | 0.75 | PARP10 (0.51) | PARP10KDM4EALDH1A1SMN1; SMN2SYK | |
| SCHEMBL27299169 | 0.75 | FFAR1 (0.53) | PARP10KDM4EALDH1A1SMN1; SMN2SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1756051-B1 | Histamine H3 receptor agents, preparation and therapeutic uses | LILLY CO ELI (US) | 2012-09-12 | — | — | EP | disclosed |
| US-7696234-B2 | (4-Benzyloxy-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)- methanone; obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases | ELI LILLY AND COMPANY (US) | 2010-04-13 | — | — | US | disclosed |
| US-20090118254-A1 | (4-Benzyloxy-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)- methanone; obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases | ELI LILLY AND COMPANY | 2009-05-07 | — | — | US | disclosed |
| EP-1756051-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005121080-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118254-A1 | (4-Benzyloxy-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)- methanone; obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases | HRH3, HRH4, HCRTR1 | PARP10 1075/4885PPARG 410/4885KDM4E 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.